Close Menu

The editor-in-chief of Science decries Pfizer's subpoena served on the New England Journal of Medicine. Pfizer is being sued by plaintiffs who say that Celebrex and Bextra cause cardiovascular and other injuries, and some of them may point to NEJM papers to back up their claims. Pfizer, then, wants to look through the confidential peer-reviews of those, saying the public has no interest in protecting the editorial process of a journal.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.